downside of glp 1 GLP-1 Medications: Everything You Need to Know GLP-1 Agonists For Obesity In

Characterization of the Responses of Circulating Glucagon-Like Immunoreactivity to Intraduodenal and Intravenous Administration of Glucose

10.1016/j.cell.2019.08.003 101 RiveraD.OniskoN.CaoJ

Only 0.008% reported subsequent hair regrowth during the study periods

Cells exposed to 16.8 mM glucose in the presence of 100 nM Exendin-4-Fc showed a significant increase in insulin mRNA level, as compared to those without Exendin-4-Fc, while cells exposed to 2.8 mM glucose only showed no significant change in insulin mRNA level with or without Exendin-4-Fc

Factors Affecting Weight Loss Results with GLP-1 Agonists Individual Variation Individual characteristics such as metabolism, genetics, and baseline weight significantly influence weight loss outcomes when using GLP-1 agonists

Trajectory of BMI change after discontinuation of AOMs Regarding to BMI change, it was also different at specific follow-up time points after treatment discontinuation